Ostarine (MK-2866) is an androgen receptor modulator (SARM). Ostarine (MK-2866) has an tissue proliferation activity on myocytes with very low or none activity on other tissues. During studies, PSA did not seem to change in males. Also, no hirutism or virilization noted in females. Ostarine (MK-2866) also resulted in a dose-dependent decrease in LDL and HDL cholesterol levels, with the average LDL/HDL ratio for all doses remaining in the low cardiovascular risk catergory.
OSTARINE MK-2866 20mg × 50Caps
Ostarine (MK-2866) is an androgen receptor modulator (SARM). Ostarine (MK-2866) has an tissue proliferation activity on myocytes with very low or none activity on other tissues. During studies, PSA did not seem to change in males. Also, no hirutism or virilization noted in females. Ostarine (MK-2866) also resulted in a dose-dependent decrease in LDL and HDL cholesterol levels, with the average LDL/HDL ratio for all doses remaining in the low cardiovascular risk catergory.
Ostarine ((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) (also known as GTx-024 and MK-2866) is an investigational selective androgen receptor modulator (SARM) from GTX, Inc for potential therapeutic benefit of conditions such as muscle wasting and osteoporosis, formerly under development by Merck & Company.
Description:
Formula : C19H14F3N3O3
Mol. Mass: 389.33 g/mol